$77.81-2.5%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Company outlook: revenue of $520M to $530M for Fiscal year 2026 — up 38.2% on a year earlier
Just reported
From CareDx, Inc.'s results release of October 29, 2026; its quarterly report has since been filed.
Actual
$139.4M
+39% y/y
+5.6% q/q
Guided
—
No guide given
Actual
$0.35
-83% q/q
Guided
—
No guide given
Actual
$8.1M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $139.4M | $100.1M | +39.29% |
| Profit | $19.3M | $1.7M | +1,051.76% |
| Profit per share | $0.35 | $0.03 | +1,066.67% |
| Free Cash Flow | $11.1M | $8.9M | +24.92% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
CareDx, Inc. has no earnings call transcript available.
“We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from CareDx, Inc.’s Item 2.02 8-K filed October 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
-93% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.